M Pharmaceutical Inc. Enters into Exclusive Negotiations…

M Pharmaceutical Inc. (CSE:MQ, OTCQB: MPHMF, FWB:T3F2 ), (the “Company” or “M Pharma”), is announcing that the Company has entered into a 30 day exclusive negotiating period in respect to a possible  acquisition of a private pharmaceutical company which holds an FDA approved women’s health product.

As M Pharma moves ahead  with its recently acquired patented Chelatexx technology and its existing Trimeo weight loss capsules, the Company is taking steps to broaden its portfolio of drug treatments and biomedical technologies beyond the obesity field.

“With this potential acquisition, we would expand into the women’s health market.  Our initial review of the product under investigation leads us to believe that this would be a potential breakthrough product in the women’s health space,” noted M Pharma President & CEO, Mr. Brian Keane.

 

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management.  In addition to its recent acquisition of C-103, a reformulation of Orlistat from Chelatexx, LLC, the Company will focus on the development of itsTrimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

 

For more information contact:

Investor Relations

Phone: +1 604 428 0511

info@m-pharma.ca

www.m-pharma.ca

 

 

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.